Pyrophosphate imaging agent shortage reported, could last weeks

The American Society of Nuclear Cardiology (ASNC) is alerting its provider members of a pyrophosphate shortage, which could potentially last for weeks. 

The ASNC has received reports of imaging agent 99mTechnetium-pyrophosphate (PYP) being in low supply, citing statements it received from two manufacturers, Curium and Sun Radiopharma, who blame the shortage on supply chain disruptions.

According to the ASNC, Curium said it is working to find an alternative supplier to resume normal production as soon as possible. In its own statement, Sun Radiopharma provided a “best estimate” of January 2024 for PYP production to resume as normal.

The company also lists shortages in other radiopharmaceutical products, with estimates for when supplies will be available. The full statement from Sun Radiopharma can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.